Recurrent or Refractory Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Recurrent or Refractory Ascites Market Outlook

Thelansis’s “Recurrent or Refractory Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Refractory Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent or Refractory Ascites Overview

Ascites refer to the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often indicating the transition from compensated to decompensated cirrhosis. Refractory ascites (RA) is a term defined by the International Club of Ascites (ICA) as ascites that recur within 4 weeks after large-volume paracentesis (LVP) and are resistant to medical therapy. Recurrent ascites, defined as ascites recurring at least three times within 12 months, impact survival differently than RA, and its effects on survival are yet unknown. Refractory ascites, occurring in 5%–10% of all patients with cirrhotic ascites, is associated with a high mortality rate, with an average 1-year survival rate of around 50%. Large-volume paracentesis, the primary treatment for refractory ascites, involves directly aspirating more than 5 liters of ascites. While LVP can rapidly control massive ascites and reduce hospital stays compared to diuretics, it does not affect the mortality rate. Patients with refractory ascites may require repeated paracentesis, leading to poor compliance, reduced quality of life, and increased risks of complications such as paracentesis-induced circulatory dysfunction (PICD), bleeding, and infections. Individuals with a blood platelet count below 50,000/mm3, those classified as Child-Pugh class C, and those with a history of alcoholism are at an elevated risk of developing PICD.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: